Tag Archive for: neurology

Vesper Bio initiates Phase Ib/IIa proof of concept study of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia (FTD)

/in

Dosing of VES001 has commenced in patients with causal gene mutations for FTD(GRN), a type of frontotemporal dementia which is invariably fatal This follows Vesper having received clinical trial authorisation from the Netherlands and the United Kingdom to initiate its Phase Ib/IIa “SORT-IN-2” trial VES001 is a first-in-class, potentially disease-modifying, orally-dosed, brain-penetrant treatment for FTD(GRN), […]

Read more

Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies

/in

New therapies will allow patients greater choice and flexibility in the control of CNS disorders Barcelona, Spain / Düsseldorf, Germany and Athens, Greece – 12 December 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in […]

Read more

Neuraxpharm expands operations into the Middle East

/in

Brings leading CNS products, including BRIUMVI® (ublituximab), to new territories Dubai, UAE, Barcelona, Spain and Düsseldorf, Germany – 1st October, 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of Neuraxpharm Middle East to cover the six members of the Gulf Cooperation […]

Read more

Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP Healthcare Venture Management to develop a protein stabilisation pipeline

/in

Proprietary E3 ligase platform to enable protein stabilisation “at source”, thereby restoring the body’s sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges of drugging these targets Pipeline of first-in-class, small molecule, E3 ligase inhibitors to stabilise proteins and treat disease in several therapeutic areas, including […]

Read more

European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm

/in

Decision is not due to any public health concerns regarding generic DMF products Neuraxpharm to swiftly contest this decision at the General Court of the European Union Barcelona and Düsseldorf – 20 December, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces […]

Read more
© Optimum Strategic Communications.